Clinical Briefings™: Optimizing Cosmetic Outcomes – Advances in Neurotoxic Agents and Biostimulatory Soft Tissue Fillers

Released On
March 3, 2020

Expires On
March 3, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Dermatology, Obstetrics & Gynecology

 

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC..

Supported by an educational grant from Allergan.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.0 Contact Hour.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward dermatologists, plastic surgeons, facial plastic surgeons, ocular plastic surgeons, ophthalmologists, and medical professionals from the following disciplines: dermatology, plastic surgery, otolaryngology, ophthalmology, dermatologic surgery, cosmetic surgery, facial plastic surgery, and ocular plastic surgery. It may also be of benefit to nurses in the field of aesthetic medicine and other healthcare providers who are involved in aesthetic medicine.

Program Overview

Facial aging is the result of a combination of changes that involve the skin and underlying tissues. Overall, the changes that result from underlying volume loss and wrinkling associated with age and photodamage can produce a subjectively older appearance. This CME-certified activity entitled, “Clinical Briefings™: Optimizing Cosmetic Outcomes – Advances in Neurotoxic Agents and Biostimulatory Soft Tissue Fillers,” will help physicians select the right tools to optimize outcomes and increase patient satisfaction using a patient-tailored approach.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explicate the various soft-tissue filler and neurotoxin agents available determined by product characteristics, sites of correction, and safety
  • Discuss optimization of cosmetic results through combined approach of neurotoxin and soft-tissue filler therapy
  • Discern the clinical impact of recent advances in neurotoxin and soft-tissue filer agents in cosmetic care of patients

Faculty

Sabrina Guillen Fabi, MD, FAAD, FAACS

Goldman Butterwick Groff Fabi & Wu, Cosmetic Laser Dermatology
Voluntary Assistant Clinical Professor in Medicine/Dermatology
University of California
San Diego, CA

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Disclosures of Conflicts of Interest

Sabrina Guillen Fabi, MD, FAAD, FAACS

  • Consultant: Allergan, Merz, Galderma, Revance, Bausch Health Companies Inc, Endo; Speakers Bureau: Allergan, Merz, Galderma;
  • Stock/Shareholder: Allergan, Revance.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.